ESR1 and breast carcinoma: Giredestrant, a non-steroidal, oral, selective ER antagonist and SERD, has shown promise in phase II trials as a single-agent drug therapy to treat locally advanced or metastatic breast cancer with an ER-positive, HER-negative profile (171, 173).